TRFT for primary and metastatic brain cancers
exploratoryresearch program · medium · Fri Aug 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate whether in-home transcranial radiofrequency waves can induce regression or elimination of primary and metastatic brain cancers.
Proposed non-thermal, non-invasive TRFT monotherapy or combination with immune checkpoint inhibitors, acting through enhanced meningeal lymph flow, cytokine immune rebalancing, and direct anti-proliferative effects in the tumor microenvironment.
2025 Cancers perspective article argued that existing animal and human clinical evidence justifies immediate clinical testing of TRFT against primary and metastatic brain cancers.
No completed brain cancer clinical trial results are supplied; the article presents preclinical and clinical rationale and proposed mechanisms.
MemorEM in-home TRFT device
exploratoryconsumer product · high
Provide in-home, caregiver- or self-administered transcranial radiofrequency treatment to the brain.
8-emitter head device delivering TRFT at 915 MHz; reported use includes daily 1-hour or twice-daily 1-hour sessions in Alzheimer's disease subjects and phantom testing at 4.0 W/kg SAR.
2025 phantom study reported that 1-hour TRFT at 4.0 W/kg SAR did not appreciably increase brain temperature, supporting potential long-term daily treatment safety at higher power.
In the phantom study, none of 64 brain-gel sites increased by 1 C or more after treatment; 45 of 64 sites rose less than 0.5 C.
Transcranial Radiofrequency Treatment (TRFT) longevity platform
exploratoryplatform · high
Increase healthy human longevity using non-invasive transcranial radiofrequency waves rather than gerotherapeutic drugs.
Bioengineered transcranial radiofrequency wave intervention delivered to the brain, described as non-thermal and non-invasive.
RF Longevity site presents TRFT as its primary longevity approach, with supporting publications on wakeful brain toxin clearance, Alzheimer's disease biomarkers, safety, and brain cancer rationale.
Supplied publications report small Alzheimer's disease studies, increased amyloid-beta and tau clearance associations, VEGF modulation, non-appreciable heating in a human head phantom, and proposed broader implications for healthy longevity.
TRFT for Alzheimer's disease brain toxin clearance
exploratoryresearch program · high
Enhance clearance of Alzheimer's disease-related brain toxins including tau and amyloid-beta, potentially improving cognition and countering age-related decline in brain cleansing.
In-home TRFT using the MemorEM device; Alzheimer's disease subjects received twice-daily 1-hour sessions for 2 months, with blood and CSF biomarker measurements before and after treatment.
2025 perspective article proposed TRFT during wakefulness as a way to enhance meningeal lymphatic vessel-mediated brain toxin cleansing; 2024 clinical biomarker study reported VEGF-associated tau and amyloid-beta clearance findings in eight mild/moderate Alzheimer's disease subjects.
Reported findings include TRFT-induced VEGF increases in subjects with low or unmeasurable baseline VEGF, increased clearance/drainage markers for tau and amyloid-beta, and reported reversal of cognitive impairment in small Alzheimer's disease studies.
